MG

This short article from the NEJM (one of the premier medical journals) by 2 FDA officials has been referenced by folks on X: nejm.org/doi/pdf/10.105… The investment implications of this memo are potentially profound. The FDA officials have unveiled a transformative regulatory framework that would eliminate randomized controlled trial requirements for gene therapies targeting clear genetic disorders. The article outlines how therapies can gain approval based on mechanistic coherence and patient outcomes rather than statistical significance. This only applies to diseases with unambiguous genetic causation - where specific mutations directly cause disease through known biological mechanisms. When companies demonstrate successful genetic correction and meaningful clinical improvement in just "several consecutive patients," the FDA will grant platform approval covering all such mutations. This replaces the traditional requirement for separate trials for each variant. The investment implications are profound. Development costs could drop from > $100mm+ to 10% of that. Approval timelines would also shrink from 10+ years to potentially 2-3 years. Probability of success increases dramatically for companies with clear mechanistic targets. NOTE: there are no advantages for companies pursuing diseases with complex or no genetic causes. Natural history data for the disease will suffice as opposed to actual controls. Instead, if science knows that gene X mutation -> loss of protein Y -> disease Z and your therapy restores protein Y function and patients improve dramatically, that's sufficient evidence. You don't need statistics to prove that fixing the root cause fixes the disease—the biology itself is the proof. This creates immediate valuation disparities. Companies with platform technologies addressing monogenic diseases -- sickle cell, muscular dystrophy, inherited blindness, rare metabolic disorders -- now face fundamentally different risk profiles than those targeting complex conditions like Alzheimer's or diabetes. $PRME, $BEAM, $CRSP, $NTLA, $SRPT